Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,734 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma.
Chen X, Wu W, Wei W, Zou L. Chen X, et al. Among authors: zou l. Front Pharmacol. 2022 Apr 26;13:869488. doi: 10.3389/fphar.2022.869488. eCollection 2022. Front Pharmacol. 2022. PMID: 35559250 Free PMC article. Review.
Chimeric antigen receptor T-cell therapy for T-ALL and AML.
Wei W, Yang D, Chen X, Liang D, Zou L, Zhao X. Wei W, et al. Among authors: zou l. Front Oncol. 2022 Nov 29;12:967754. doi: 10.3389/fonc.2022.967754. eCollection 2022. Front Oncol. 2022. PMID: 36523990 Free PMC article. Review.
A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer.
Yan M, Yuan P, Ouyang Q, Cheng Y, Han G, Wang D, Ran L, Sun T, Zhao D, Bai Y, Yang S, Wang X, Wu R, Zeng X, Yao H, Ji X, Jiang J, Hu X, Lin H, Zheng L, Zhu Z, Ge W, Yang J, Cui T, Zhang X, Lu F, Li W, Xu H, Kang M, Gong P, Zou L, Liu J, Zhang H, Yu H, Xu B. Yan M, et al. Among authors: zou l. Ther Adv Med Oncol. 2022 Oct 24;14:17588359221122715. doi: 10.1177/17588359221122715. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36330235 Free PMC article.
Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial.
Song Y, Zhou H, Zhang H, Liu W, Shuang Y, Zhou K, Lv F, Xu H, Zhou J, Li W, Wang H, Zhang H, Huang H, Zhang Q, Xu W, Ge Z, Xiang Y, Wang S, Gao D, Yang S, Lin J, Wang L, Zou L, Zheng M, Liu J, Shao Z, Pang Y, Xia R, Chen Z, Hou M, Yao H, Feng R, Cai Z, Zhang M, Ran W, Liu L, Zeng S, Yang W, Liu P, Liang A, Zuo X, Zou Q, Ma J, Sang W, Guo Y, Zhang W, Cao Y, Li Y, Feng J, Du X, Zhang X, Zhao H, Zhou H, Yu J, Sun X, Zhu J, Qiu L. Song Y, et al. Among authors: zou l, zou q. Adv Ther. 2021 Apr;38(4):1889-1903. doi: 10.1007/s12325-020-01603-8. Epub 2021 Mar 9. Adv Ther. 2021. PMID: 33751401 Clinical Trial.
5,734 results